MBX BIOSCIENCES, INC.
Ownership & governance
Executives 5Directors 8Avg age 62Avg tenure 3.4y
PH
Peter Hawryluk
Chief Executive Officer
Age 57Since 2019-12-31Profile →
+12
Executives5
PH
Peter Hawryluk→
Chief Executive Officer
Age 57Since 2019-12-31
JS
John Smither→
Director of Finance/CFO
Age 73Since 2026-02-28
AM
Andreas Moraitis→
Chief Tech/Sci/R&D Officer
—Since 2025-06-22
SH
Stewart Hallett→
Chief Tech/Sci/R&D Officer
—Since 2023-12-31
EF
Elisa Fabbrini→
Chief Tech/Sci/R&D Officer
—Since 2024-03-31
Board of directors8
PH
Peter Hawryluk→
Chairman
Age 57Since 2019-12-31
EM
Ed Mathers Mathers→
Director/Board Member
Age 66Since 2020-06-30
PH
Patrick Heron→
Director/Board Member
Age 55Since 2020-06-30
OP
Ora Pescovitz→
Director/Board Member
Age 69Since 2022-04-04
TA
Tiba Aynechi→
Director/Board Member
Age 50Since 2022-11-30
SR
Steven Ryder→
Director/Board Member
Age 75Since 2023-12-31
SH
Steven Hoerter→
Chairman
Age 55Since 2025-11-05
LS
Laurie Stelzer→
Director/Board Member
Age 58Since 2026-01-19
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Frazier Life Sciences Management LP | 14 % | 6,652,013 |
| OrbiMed Advisors Private Equity | 7.657 % | 3,637,887 |
| NEA Management Co. LLC | 7.608 % | 3,614,486 |
| Wellington Trust Co., NA | 6.718 % | 3,191,824 |
| Fidelity Management & Research Co. LLC | 6.181 % | 2,936,684 |
Catalog · 2026-07-09
SEC officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Andreas Moraitis | Chief Tech/Sci/R&D Officer | — | - |
| Elisa Fabbrini | Chief Tech/Sci/R&D Officer | — | - |
| John Smither | Chief Financial Officer | — | - |
| Peter Hawryluk | Chairman | — | - |
| Steven Hoerter | President and Chief Executive Officer | — | - |
| Stewart Hallett | Chief Tech/Sci/R&D Officer | — | - |
| Ed Mathers Mathers | Director/Board Member | — | - |
| Laurie Stelzer | Director/Board Member | — | - |
SEC · as of 2026-07-13
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 95.7Range 80–150Analysts 10
80Mean 95.7150
- Strong buy 3
- Buy 8
Broker actions26
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Stifel | Maintained | Buy | 84 | 2026-10-12 |
| Guggenheim | Maintained | Buy | 150 | 2026-10-02 |
| Truist Securities | Maintained | Buy | 88 | 2026-08-10 |
| Mizuho | Maintained | Outperform | 91 | 2026-07-29 |
| Barclays | Maintained | Overweight | 70 | 2026-05-12 |
| Citizens | Maintained | Market Outperform | 86 | 2026-05-12 |
| Truist Securities | Maintained | Buy | 70 | 2026-05-11 |
| Barclays | Initiated | Overweight | 66 | 2026-01-28 |
| Guggenheim | Maintained | Buy | 88 | 2026-01-16 |
| UBS | Initiated | Buy | 60 | 2026-01-07 |
| Stifel | Maintained | Buy | 50 | 2025-12-19 |
| Goldman Sachs | Initiated | Sell | 18 | 2025-12-04 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.